查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球線粒體肌病治療市場（2022-2029）
市場調查報告書
商品編碼
1078249

全球線粒體肌病治療市場（2022-2029）

Global Mitochondrial Myopathies Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告調查全球線粒體肌病治療市場，包括市場概況、市場規模和預測、趨勢、增長因素和挑戰、客戶情況、類型/測試類型/藥物類型/治療類型/分佈。我們提供渠道分析/地區，以及公司簡介。

目錄

第1章調查方法及範圍

  • 調查方法
  • 調查的目的和範圍

第2章市場定義和概述

第 3 章執行摘要

  • 按類型劃分的市場細分
  • 按檢查類型劃分的市場細分
  • 按藥物類型劃分的市場細分
  • 按治療類型劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第4章市場動態

  • 影響市場的因素
    • 促進因素
    • 抑制器
    • 市場機會
    • 影響分析

第5章行業分析

  • 供應鏈分析
  • 價格分析
  • 未滿足的需求

第 6 章 COVID-19 分析

  • 分析 COVID-19 對市場的影響
    • 之前的 COVID-19 市場情景
    • 當前 COVID-19 市場情況
    • COVID-19 後或未來情景
  • COVID-19 的價格波動
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略計劃
  • 結論

第 7 章按類型

  • 簡介
    • 按類型和同比增長分析的市場規模分析
    • 按類型劃分的市場吸引力指數
  • Kearns-Sayer 綜合徵
    • 簡介
    • 市場規模分析（2020-2029 和 2021-2029）
  • 線粒體 DNA 耗竭綜合徵 (MDS)
  • 線粒體腦肌病、乳酸性酸中毒和中風樣發作 (MELAS)
  • 孕產婦耳聾和糖尿病 (MIDD)
  • 線粒體神經胃腸道腦肌病 (MNGIE)
  • 肌陣攣性癲癇伴破舊的紅纖維 (MERRF)
  • 神經病變、共濟失調和色素性視網膜炎 (NARP)
  • 皮爾遜綜合徵
  • 其他

第 8 章按檢查類型

  • 簡介
    • 按檢查類型和同比增長分析的市場規模分析
    • 按檢查類型劃分的市場吸引力指數
  • 基因檢測
    • 簡介
    • 市場規模分析（2020-2029 和 2021-2029）
  • 肌肉活檢
  • 血□檢測
  • 其他檢查

第 9 章按藥物類型

  • 簡介
    • 藥物類型市場規模分析及同比增長分析
    • 按藥物類型劃分的市場吸引力指數
  • 輔□Q10
    • 簡介
    • 市場規模分析（2020-2029 和 2021-2029）
  • 左旋肉鹼
  • 肌酸
  • 其他

第 10 章按治療類型

  • 簡介
    • 按治療類型和同比增長分析的市場規模分析
    • 按治療類型劃分的市場吸引力指數
  • 維生素
    • 簡介
    • 市場規模分析（2020-2029 和 2021-2029）
  • 抗氧化
  • 支持性和靶向治療
  • 其他

第 11 章按分銷渠道

  • 簡介
    • 分銷渠道市場規模分析和同比增長分析
    • 按分銷渠道劃分的市場吸引力指數
  • 醫院藥房
    • 簡介
    • 市場規模分析（2020-2029 和 2021-2029）
  • 零售藥店
  • 網上藥店
  • 其他

第 12 章按地區

  • 簡介
    • 區域市場規模分析（2020-2029 年和 2021-2029 年）
    • 各地區市場吸引力指數
  • 北美
    • 簡介
    • 特定地區的主要動態
    • 按類型和同比增長分析的市場規模分析
    • 按檢查類型和同比增長分析的市場規模分析
    • 藥物類型市場規模分析及同比增長分析
    • 按治療類型和同比增長分析的市場規模分析
    • 分銷渠道市場規模分析和同比增長分析
    • 特定國家市場規模分析和同比增長分析
  • 歐洲
    • 簡介
    • 特定地區的主要動態
    • 按類型和同比增長分析的市場規模分析
    • 按檢查類型和同比增長分析的市場規模分析
    • 藥物類型市場規模分析及同比增長分析
    • 按治療類型和同比增長分析的市場規模分析
    • 分銷渠道市場規模分析和同比增長分析
    • 特定國家市場規模分析和同比增長分析
  • 南美洲
    • 簡介
    • 特定地區的主要動態
    • 按類型和同比增長分析的市場規模分析
    • 按檢查類型和同比增長分析的市場規模分析
    • 藥物類型市場規模分析及同比增長分析
    • 按治療類型和同比增長分析的市場規模分析
    • 分銷渠道市場規模分析和同比增長分析
    • 特定國家市場規模分析和同比增長分析
  • 亞太地區
    • 簡介
    • 特定地區的主要動態
    • 按類型和同比增長分析的市場規模分析
    • 按檢查類型和同比增長分析的市場規模分析
    • 藥物類型市場規模分析及同比增長分析
    • 按治療類型和同比增長分析的市場規模分析
    • 分銷渠道市場規模分析和同比增長分析
    • 特定國家市場規模分析和同比增長分析
  • 中東和非洲
    • 簡介
    • 特定地區的主要動態
    • 按類型和同比增長分析的市場規模分析
    • 按檢查類型和同比增長分析的市場規模分析
    • 藥物類型市場規模分析及同比增長分析
    • 按治療類型和同比增長分析的市場規模分析
    • 分銷渠道市場規模分析和同比增長分析

第13章競爭態勢

  • 主要發展及戰略
  • 企業份額分析
  • 產品基準
  • 知名大公司名單

第 14 章公司簡介

  • Pfanstiehl, Inc.
    • 公司簡介
    • 產品組合/類型
    • 主要亮點
    • 財務概覽
  • Ajinomoto Co., Inc.
  • BOTAY BIO-CHEM CO., LIMITED
  • Xi'an ZB Biotech Co., Ltd.
  • Kaneka Corporation
  • Lonza
  • AdvaCare Pharma
  • NutraBio Labs, Inc.

第 15 章全球線粒體肌病治療市場：DataM

  • 附錄
  • 關於我們公司/應用
  • 聯繫我們
簡介目錄
Product Code: DMPH5158

Market Overview

The global mitochondrial myopathies treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Mitochondrial disorders are inherited chronic conditions marked by a variety of biochemical and genetic mitochondrial abnormalities and mutations. The condition affects the brain, heart, liver, skeletal muscles, kidneys, and respiratory systems, among other organs. Patients with mitochondrial disorders frequently experience muscle weakness, exercise intolerance, and weariness as a result of a reduction in mitochondrial respiration caused by mitochondrial DNA abnormalities that result in a decreased ability to synthesize cellular adenosine triphosphate (ATP). The majority of vitamins, co-factors, off-label medications approved for other reasons, and nutritional supplements are used to treat mitochondrial problems.

Market Dynamics

Innovative therapies in the clinical trials for the treatment of Mitochondrial Myopathies are expected to drive market growth.

Mitochondrial illnesses are genetically based, neither metabolic pathways nor symptomatic treatments can fundamentally fix them. Gene therapy is therefore the best option. Most advances in mitochondrial disease gene therapy have so far been focused on LHON. Pathogenic mutations of the mtDNA encoding complex IV subunit 4 are seen in about 70% of people with LHON (MT-ND4). The adeno-associated virus (AAV) can transport mtDNA, and its capsid VP2 can fuse with a plasmid targeting sequence to reexpress ND4. The expression of wild-type ND4 in ND4 mutant cells can help to correct ATP production problems. Moreover, This is the first time gene-editing technology has been used to change mtDNA in vivo, indicating that gene-editing technologies are utilized to treat mitochondrial illnesses.

Furthermore, research has shown considerable promise and is predicted to result in more effective treatment techniques for mitochondrial illnesses. Mitochondrial biogenesis enhancers (bezafibrate, epicatechin, and RTA 408), antioxidants (RP 103 and EPI-743), and cardiolipin protectors are among the medications now being studied (elamipretide). Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Higher R&D costs, more stringent drug approval restrictions, and a lack of knowledge and understanding of the condition are some of the factors expected to hamper the market growth in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 is extremely contagious in older people with weakened immune systems, and the risk of death rises with age and the presence of comorbidities including hypertension, diabetes, cardiovascular disease, or chronic obstructive pulmonary disease. There are several theories regarding mitochondria and their functions in inflammation that could explain why SARS-CoV-2 is wreaking havoc on the older population, particularly those with comorbidities. As a result, the importance of mitochondria in treatment development has increased. Over-stimulated or sustained inflammatory responses with interferon and cytokine production, regulation of fission and fusion, mitochondrial biogenesis, and interference with apoptosis and mitophagy are all possible linkages between aging mitochondria and reduced immunity. From bacteria to parasites to viruses like SARS-CoV-2, many pathogens have shown a predisposition to disrupt mitochondria as a strategy to influence host behavior once inside a cell by changing their processes.

Additionally, the pandemic interrupts the supply chain and clinical trials process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Others segment is expected to hold the largest market share in mitochondrial myopathies treatment market

The others segment is expected to dominate in 2021. The segment is bifurcated into Mito Cocktail, Exercise, and Mitochondrial Replacement Therapy (MRT). Moreover, there is no cure for mitochondrial abnormalities, there are several treatments that might help relieve symptoms. Treatments differ from person to person and are dependent on the type of mitochondrial dysfunction that has been detected. The Mito Cocktail consists of a combination of vitamin supplements such as acetyl-L-carnitine (ALCAR), coenzyme Q10 (CoQ10), and alpha-lipoic acid (ALA), and creatine monohydrate, which is the most common form of treatment (CM). It is a scientifically based mix of vitamins, cofactors, and nutrients that are known to replace deficits that develop when the mitochondrial energy production system fails and to improve the residual function of the mitochondrial energy production system.

Additionally, One of the most useful medicines is exercise, which has been clinically verified (as long as the patient can tolerate it). On a biological level, exercise boosts energy production, which enhances mitochondrial function and increases the number of healthy mitochondria in the cells. According to studies, exercise improves exercise tolerance and metabolism by allowing the body to use oxygen more efficiently. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global mitochondrial myopathies treatment market

In 2021, North America accounted for the highest revenue share. With the increasing prevalence of Mitochondrial Myopathies, rising demand for mitochondrial-based therapeutics, advancements in diagnostic facilities, and rising number of clinical trials to develop effective drugs for the disease along with the rise in several FDA approvals for novel drugs and therapies in the region are some of the factors the market is expected to boost in the forecast period. For instance, Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) are one of the most common mitochondrial diseases, with an estimated incidence of 1 in 4000, and mitochondria are carried out in the tails of sperm cells and hence discharged outside the zygote during fertilization, only women may pass the disease on to their children.

Moreover, The North American Mitochondrial Disease Consortium (NAMDC), which is part of the Rare Disease Clinical Research Network (RDCRN), collects information from mitochondrial disease patients in a clinical patient registry, which aids researchers in finding and recruiting participants for future studies. Additionally, The US Food and Drug Administration granted orphan therapeutic status to Reneo Pharmaceutical's main drug candidate REN001, to treat primary mitochondrial myopathy in June 2020. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the mitochondrial myopathies treatment market are Pfanstiehl, Inc., Ajinomoto Co., Inc., BOTAY BIO-CHEM CO., LIMITED, Xi'an ZB Biotech Co., Ltd., Kaneka Corporation, Lonza, AdvaCare Pharma and NutraBio Labs, Inc.

Lonza Group:

Overview:

Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology, and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America, and South Asia. The company provides product development services to the pharmaceutical and biologics industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.

Product Portfolio:

Carnipure: Carnipure L-Carnitine is the nutrient needed to help support conversion of fat into metabolic energy. It provides benefits ranging from increasing blood flow, reducing markers of metabolic stress, decreasing muscle soreness and improving recovery time.

Why Purchase the Report?

  • Visualize the composition of the mitochondrial myopathies treatment market segmentation by type, test type, drug type, treatment type, distribution channel and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in mitochondrial myopathies treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of mitochondrial myopathies treatment market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global mitochondrial myopathies treatment market report would provide an access to an approx. 45+ market data table, 40+ figures and 200 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Test Type
  • 3.3. Market Snippet by Drug Type
  • 3.4. Market Snippet by Treatment Type
  • 3.5. Market Snippet by Distribution Channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Innovative therapies in the clinical trials for the treatment of Mitochondrial Myopathies are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Higher R&D costs is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Kearns-Sayre Syndrome*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Mitochondrial DNA depletion syndrome (MDS)
  • 7.4. Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)
  • 7.5. Maternally inherited deafness and diabetes (MIDD)
  • 7.6. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
  • 7.7. Myoclonus epilepsy with ragged red fibers (MERRF)
  • 7.8. Neuropathy, ataxia, and retinitis pigmentosa (NARP)
  • 7.9. Pearson syndrome
  • 7.10. Others

8. By Test Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.1.2. Market Attractiveness Index, By Test Type Segment
  • 8.2. Genetic Test*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Muscle biopsy
  • 8.4. Blood enzyme test
  • 8.5. Other tests

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type Segment
  • 9.2. CoQ10*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. L-carnitine
  • 9.4. Creatine
  • 9.5. Others

10. By Treatment Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 10.2. Vitamins*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Anti-oxidants
  • 10.4. Supportive and Targeted Therapy
  • 10.5. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Hospital Pharmacy*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacy
  • 11.4. Online Pharmacy
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. Pfanstiehl, Inc.*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Ajinomoto Co., Inc.
  • 14.3. BOTAY BIO-CHEM CO., LIMITED
  • 14.4. Xi'an ZB Biotech Co., Ltd.
  • 14.5. Kaneka Corporation
  • 14.6. Lonza
  • 14.7. AdvaCare Pharma
  • 14.8. NutraBio Labs, Inc.

LIST NOT EXHAUSTIVE

15. Global Mitochondrial Myopathies Treatment Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us